Biotech Values

[DewDiligence]

Re: MNTA’s execution against 2009 goals

Advancement of corporate strategy?

See #msg-49504093.

Completion of a study is a bonus?

I presume they awarded 100% on this item because the EMINENCE study hit its primary endpoint.

What does "advancing" Copaxone in the US mean when they filed in 2008?

It presumably refers to preparation for the Markman hearing. (The actual hearing was in 2010.)

Why did they miss financial discipline?

I don’t understand this evaluation—MNTA raised $47M in Sep 2009 on reasonably good terms, which I would’ve expected to be good for at least partial credit.

What exactly are they doing with Copaxone in the EU? I believe a clinical trial will be required.

They haven’t disclosed anything about the Copaxone program in the EU for competitive reasons.